BiologicalDrug
CDX-1140 clinical trials
Also written CDX-1140.
Keep track of what changes. Save the CDX-1140 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 8
Providence Health & Services (2) · National Cancer Institute (NCI) (2) · Craig L Slingluff, Jr (1) · Roswell Park Cancer Institute (1) · University of Texas Southwestern Medical Center (1) · HiberCell, Inc. (1) · Albert Einstein College of Medicine (1)
Often tested with
Tested in the same studies.
Pembrolizumab (3) · flt3 ligand protein (2) · 6 Melanoma Helper Peptide Vaccine (1) · Oxaliplatin (1) · Capecitabine (1) · CDX-301 (1) · BTH1677 (1)
Studies
Open first, then newest update. How each study uses CDX-1140 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06980038Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05849480Written as CDX-1140
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT05231122Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerRecruitingPhase 1University of Texas Southwestern Medical CenterNCT05029999Written as CDX-1140
- Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingPhase 1Providence Health & ServicesNCT05349890Written as CDX-1140
- Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingPhase 1Providence Health & ServicesNCT04520711Written as CDX-1140
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)CompletedPhase 1/2Craig L Slingluff, JrNCT04364230Written as CDX-1140
- A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 1HiberCell, Inc.NCT05484011Written as CDX-1140
- FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic RadiotherapyTerminatedPhase 1/2Albert Einstein College of MedicineNCT04491084Written as anti-CD40 antibody (CDX-1140)
Given in every arm · 3 — CDX-1140 is usual care beside what is tested
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT04616248Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer PatientsTerminatedPhase 2Washington University School of MedicineNCT04536077Written as CDX-1140
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedPhase 1Celldex TherapeuticsNCT03329950Written as CDX-1140
Codes
What other systems call CDX-1140 · ClinicalTrials.gg INT017506
- UNII (FDA) OWK8BG0FO6CDX-1140One source FDA
- NCI Thesaurus C150558Anti-CD40 Agonist Monoclonal Antibody CDX-1140One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OWK8BG0FO6 | CDX-1140 | One source FDA |
| NCI Thesaurus | C150558 | Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.